Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12284433 | 0.83 | — | — | |
| SCHEMBL19373837 | 0.83 | — | — | |
| SCHEMBL2600181 | 0.81 | HRH4 (0.34) | — | |
| SCHEMBL10177795 | 0.79 | HRH4 (0.37) | — | |
| SCHEMBL19934928 | 0.79 | — | — | |
| SCHEMBL238451 | 0.78 | KDM4E (0.34) | KDM4EALDH1A1 | |
| SCHEMBL19750385 | 0.77 | CYP2C19 (0.39) | ALDH1A1 | |
| SCHEMBL18591728 | 0.77 | HRH4 (0.39) | — | |
| SCHEMBL13884336 | 0.77 | HRH4 (0.39) | — | |
| SCHEMBL18025230 | 0.77 | HRH4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238212-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| WO-2024126549-A1 | SOLUTION FOR POST ETCH RESIDUE REMOVAL (PERR) | BASF SE (DE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024126588-A1 | SOLUTION FOR POST ETCH RESIDUE REMOVAL (PERR) | BASF SE (DE) | 2024-06-20 | — | — | WO | disclosed |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230365610-A1 | Aryl Glucoside Derivative | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365610-A1 | Aryl Glucoside Derivative | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20080260679-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | RELYPSA, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080241092-A1 | Administering a potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic | RELYPSA, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080241093-A1 | A potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic | RELYPSA, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080233073-A1 | Administering potassium binding polymer of alpha-fluoroacrylic acid comprising counterion of calcium crosslinked with divinylbenzene, (m)ethylenebisacrylamide, N,N'-bis(vinylsulfonylacetyl) ethylene diamine, 1,3-bis(vinylsulfonyl) 2-propanol, vinylsulfone, polyvinyl ether, polyallylether; hyperkalemia | RELYPSA, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080125552-A1 | Low-Viscosity Microcapsule Dispersions | BASF AKTIENGESELLSCHAFT PATENTS, TRADEMARKS AND LICENSES (DE) | 2008-05-29 | — | — | US | disclosed |
| US-20080103265-A1 | Microcapsule Dispersions | BASF AKTIENGESELLSCHAFT (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20070264505-A1 | Resistant to the adsorption of proteins, cells and bacteria; have a chemical chain bonded thereon that comprise a terminal group free of a hydrogen bond donor or where a hydrogen bond donor is sufficiently buried | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-7276286-B2 | Surfaces that resist the adsorption of biological species | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260679-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | SLC10A1, SLC9A5, SLC9A3 | KDM4E 4372/4885ALDH1A1 2758/4885 |
| US-20080233073-A1 | Administering potassium binding polymer of alpha-fluoroacrylic acid comprising counterion of calcium crosslinked with divinylbenzene, (m)ethylenebisacrylamide, N,N'-bis(vinylsulfonylacetyl) ethylene diamine, 1,3-bis(vinylsulfonyl) 2-propanol, vinylsulfone, polyvinyl ether, polyallylether; hyperkalemia | KCNH3, KCNAB1, KCNMB1 | KDM4E 1050/4885ALDH1A1 2931/4885 |
| US-20080241092-A1 | Administering a potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic | KCNN3, ATP6V1B1, KCNK3 | KDM4E 1298/4885ALDH1A1 3658/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | KDM4E 3553/4885ALDH1A1 2338/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | KDM4E 1076/4885ALDH1A1 4172/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | KDM4E 1975/4885ALDH1A1 3735/4885 |
| US-20080241093-A1 | A potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic | KCNN3, KCNK3, KCNK9 | KDM4E 1280/4885ALDH1A1 3581/4885 |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | KDM4E 720/4885ALDH1A1 454/4885 |
| US-20240238212-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | KDM4E 3784/4885ALDH1A1 4264/4885 |
| US-20230365610-A1 | Aryl Glucoside Derivative | SLC5A1, SLC5A2, SLC10A1 | KDM4E 1703/4885ALDH1A1 514/4885 |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | KDM4E 1044/4885ALDH1A1 451/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | KDM4E 4570/4885ALDH1A1 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.